This article was originally published in The Gray Sheet
Enrollment in the pivotal clinical trial of the radiation-based system for treatment of restenosis is expected to be complete by the end of the first quarter, President and CEO Thomas Weldon reports at a Jan. 11 session of the Hambrecht & Quist healthcare conference in San Francisco. As of Jan. 8, 881 patients were enrolled in the 1,100-patient study, which includes an eight-month patient follow-up period. "Our expectation is that we will do a filing for a PMA at the latest in Q1 2000," Weldon tells investors. Novoste also plans to finish enrollment by the end of the second quarter for a trial evaluating use of Beta-Cath for in-stent restenosis. As of Jan. 8, 144 of an anticipated 386 patients had been enrolled
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.
Bridges Consumer Healthcare launched by former Sanofi executives gets its first brand by acquiring North American rights to Pfizer’s ThermaCare HeatWraps brand. Pfizer divested the brand so European regulators would give antitrust clearance to its consumer JV with GSK.